Study PI(S)/Affiliation:

  • Neha Pagidipati – Duke Clinical Research
  • Emily O’Brien - Duke Clinical Research

Protocol PI(S)/Affiliation:

  • Wenke Hwang, Penn State University/Milton S. Hershey Medical Center
  • Michael Wesley Milks, Ohio State University

Purpose/Goal(s): Lipoprotein (a) [Lp(a)] is a strong marker for Cardiovasular (CV) risk. Perhaps because there has not been a clear therapy for elevated Lp(a), this marker is rarely checked in practice. As novel therapies become available, it will be important to increase physician awareness and testing of Lp(a). First, we must understand which patients are having their Lp(a) checked in real-world settings, and what happens to these patients.


  • Describe the demographic, clinical, and laboratory characteristics of individuals with Lp(a) testing compared with those who had only LDL checked within a similar time frame
  • Describe the characteristics of providers who ordered Lp(a)
  • Summarize temporal patterns of Lp(a) testing in a real-world population
  • Evaluate the relationship between Lp(a) level and:
    • subsequent use of lipid-lowering therapy
    • clinical outcomes

Study Design: Query based on data in the PCORnet CDM 4.1

PaTH Partners:

  • Penn State University/Milton S Hershey Medical Center
  • Ohio State University/Wexner Medical Center

Sponsor: Amgen

Coordinating Center: Duke Clinical Research Institute

PaTH Network Logo
Twitter Logo Facebook Logo LinkedIn Logo YouTube Logo

Copyright 2016 | PaTH Network